Saponin Nanoparticle Adjuvants Incorporating Toll-Like Receptor Agonists Improve Vaccine Immunomodulation.
Saponin Nanoparticle Adjuvants Incorporating Toll-Like Receptor Agonists Improve Vaccine Immunomodulation.
复制标题
含有 Toll 样受体激动剂的皂苷纳米颗粒佐剂可改善疫苗免疫调节。
DOI：
10.1101/2023.07.16.549249
复制
发表时间：
2023
期刊：
影响因子：
--
通讯作者：
Appel,Eric
中科院分区：
文献类型：
--
作者：
Ou,BenS;Baillet,Julie;FilsingerInterrante,MariaVictoria;Adamska,JuliaZ;Zhou,Xueting;Saouaf,Olivia;Yan,Jerry;Klich,John;Jons,CarolynK;Meany,Emily;Valdez,AdianS;Carter,Lauren;Pulendran,Bali;King,NeilP;Appel,Eric
Over the past few decades, the development of potent and safe immune-activating adjuvant technologies has become the heart of intensive research in the constant fight against highly mutative and immune evasive viruses such as influenza, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and human immunodeficiency virus (HIV). Herein, we developed a highly modular saponin-based nanoparticle platform incorporating Toll-like receptor agonists (TLRas) including TLR1/2a, TLR4a, and TLR7/8a adjuvants and their mixtures. These various TLRa–saponin nanoparticle adjuvant constructs induce unique acute cytokine and immune-signaling profiles, leading to specific T helper responses that could be of interest depending on the target disease for prevention. In a murine vaccine study, the adjuvants greatly improved the potency, durability, breadth, and neutralization of both COVID-19 and HIV vaccine candidates, suggesting the potential broad application of these adjuvant constructs to a range of different antigens. Overall, this work demonstrates a modular TLRa-SNP adjuvant platform that could improve the design of vaccines and affect modern vaccine development.
